✓ Medically reviewed by · Last reviewed: May 2026
Pharmacy Researcher · 8 years experience
Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.
You started Ozempic or Wegovy in January. The scale dropped fast for the first 12 weeks — then somewhere around month four, the line went flat. Maybe it ticks down half a kilo, then back up. Maybe nothing for three weeks running. You are not doing anything wrong. You have hit the GLP-1 plateau — the most predictable, most documented, and most fixable phase of any semaglutide or tirzepatide protocol.
This guide pulls apart what the month-4 stall actually is, the biology that drives it (metabolic adaptation, ghrelin rebound, sub-optimal dose, lifestyle drift), what the published STEP-1, SURMOUNT-1 and STEP-4 weight curves show, and the eight evidence-backed levers clinicians use to break a stall. There is also a hard answer for when a plateau is the body telling you it is done losing — and pushing through would be a mistake.
Key Takeaways
- The month-4 GLP-1 plateau is built into the published weight curves of every Phase 3 trial — STEP-1, SURMOUNT-1 and STEP-4 all show it.
- Mean weight loss continues for ~60–68 weeks but at a slowing rate; the fastest losses are months 1–3.
- Plateaus around month 4 are usually multi-causal: metabolic adaptation, sub-maximal dose, lifestyle drift, and natural variance combine.
- The single highest-yield intervention is usually a dose titration up if you are below the labelled maximum (2.4 mg semaglutide, 15 mg tirzepatide).
- Protein at 1.6–2.2 g/kg, resistance training, and a sleep audit address the lean-mass-loss component that lowers your daily calorie burn.
- Not every plateau is a problem — if BMI is in healthy range, the plateau may be the body’s new defended weight.
Reviewed by Morgan Ellis, Clinical Pharmacy Editor · Last updated: 15 May 2026
Jump to: What the month-4 stall is · Why it happens · The 6 plateau causes · Safety while breaking it · The research · Strategies compared · 8 levers to break it · FAQs · Bottom line
What is the GLP-1 plateau and the month-4 stall?
Quick definition: The GLP-1 plateau is the slow-down or pause in weight loss that typically appears between weeks 12 and 24 of semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound) or other GLP-1 therapy. The “month-4 stall” is the most-reported version of it — a 2–6 week stretch around weeks 14–20 where the scale stops moving despite the medication still working. It is a published feature of every Phase 3 trial weight curve, not a sign of treatment failure.
The pharma trial data are unambiguous. In SURMOUNT-1 (tirzepatide for obesity), the mean weight-loss curve falls steeply for the first 12 weeks, then continues to fall at a slowing rate through about week 60 before flattening completely. In STEP-1 (semaglutide for obesity), the same shape: steep months 1–3, gradual months 4–12, asymptote around month 16. The “stall” is the second derivative of that curve becoming visible to the person standing on the scale.
Individual variance, however, is large. The mean curve hides cohorts who lose steadily through month 12, cohorts who plateau at month 3 and stay there, and cohorts who lose more in months 6–12 than they did in months 1–3. The month-4 stall is the most common pattern, but it is not universal.
Two distinctions matter. A “plateau” is a multi-week pause where mean weight is roughly flat. “Weight noise” is the 1–2 kg of normal daily variance from food residue, hydration and hormonal water shifts. Three days of no movement is noise. Three weeks of no movement is a plateau worth analysing.
How does the GLP-1 plateau actually work?
At the simplest level, weight loss stops when daily energy intake equals daily energy expenditure. Both sides of that equation move during GLP-1 therapy, and the month-4 plateau is what happens when they cross. Four mechanisms drive most of the convergence.
- Metabolic adaptation. Resting metabolic rate falls as body mass falls, plus a few hundred extra calories beyond what mass-loss alone would predict (“adaptive thermogenesis”). Roughly: losing 15 kg lowers resting daily calorie burn by 200–400 kcal.
- Hormonal counter-regulation. Ghrelin (the hunger hormone) rises with weight loss, leptin (the satiety hormone) falls, and thyroid hormone trends lower. These shifts increase appetite and reduce energy output. Semaglutide and tirzepatide partially counter ghrelin, but only partially.
- Submaximal dose. Many people stall on a dose that worked at the start because that dose was right for their starting body weight, not their current one. The labelled titration schedule (2.5 → 5 → 10 → 15 mg tirzepatide; 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg semaglutide) exists precisely for this.
- Behavioural drift. Early Ozempic adherence often involves dramatic appetite suppression and effortless calorie reduction. As tolerance to GI side effects builds, appetite re-asserts itself partially, snacking creeps back, and the original behavioural delta narrows.
The reason month 4 is the common landing zone is mathematics. Months 1–3 represent the biggest behavioural delta from baseline. By month 4, the body has down-regulated its energy needs, dose has not yet been escalated to the maximum, and the easy wins are already taken. The remaining gap between intake and expenditure shrinks toward zero.
🔬 Research Spotlight
In STEP-4 (Rubino et al., JAMA, 2021), participants who continued semaglutide 2.4 mg past week 20 kept losing weight to week 68; those switched to placebo at week 20 regained. The implication is direct: the slowdown around week 16–20 is not the drug “stopping working”. It is the dose-response curve flattening. The same agent at the same dose still produces durable effect — just at a slower pace. Research suggests dose escalation, mechanism switch, or lifestyle scaffolding extends the active losing phase.
The six causes of a month-4 plateau — and what each tells you
Most stalls have more than one cause. Walking through these in order is the diagnostic framework most experienced clinicians use. The fix depends on which boxes you tick.
1. Sub-maximal dose
The single most common cause. If you are on 5 mg tirzepatide and have not yet escalated to 10 mg, or on 1.0 mg semaglutide and have not yet escalated to 1.7 or 2.4 mg, the dose is doing what it can — but it was sized for a heavier you. Dose titration upward (when tolerated) is the highest-yield single lever in most plateaus.
2. Calorie target outdated
Your daily calorie need is a function of body mass. A person who needed 2,200 kcal/day at 95 kg needs perhaps 1,900 kcal/day at 80 kg. The same “I’m barely hungry” pattern that was a deficit in month 1 may be maintenance by month 4. Tracking intake honestly for 7 days — just once, as a diagnostic — reveals this fast.
3. Lean mass loss
GLP-1 therapy typically loses 25–40% of weight as lean tissue without resistance training. Each kilo of lean tissue lost lowers daily metabolic rate. By month 4, accumulated lean loss may have lowered your daily burn by 100–200 kcal beyond mass-related expectations.
4. Protein deficit
Reduced appetite often reduces protein intake disproportionately, because protein takes more chewing and feels more “full” than carbs. Below ~1.6 g/kg protein, lean mass loss accelerates and satiety drops in parallel. Protein is the single most-cited macro fix in obesity-medicine practice.
5. Sleep / stress / cortisol
Sleep loss raises ghrelin and cortisol, lowers leptin, and increases insulin resistance — all of which fight the GLP-1 effect. A run of poor sleep around month 4 is a common silent plateau driver.
6. Pure variance
Some plateaus are just statistical noise — especially in women across menstrual cycles, where water-weight shifts can mask 1–2 weeks of real fat loss. If the tape measure is shrinking but the scale isn’t, the plateau may already be over and the scale just hasn’t caught up.
👤 Who Is This For?
This guide is for adults currently on Ozempic, Wegovy, Mounjaro, Zepbound or another GLP-1 medication who have hit a 2+ week stall somewhere between weeks 12 and 24. It is also useful for clinicians sketching the conversation with a frustrated patient at month 4. It does not apply if you have a healthy BMI already, are using GLP-1 therapy for type 2 diabetes glycaemic control rather than weight loss, or have only stopped losing for under 14 days — those scenarios need different framing.
Safety when escalating dose or breaking a plateau
The two most-used plateau interventions — dose escalation and aggressive calorie tightening — both have side-effect profiles worth respecting. The table below shows what changes risk during a plateau-breaking phase.
| Side effect | Frequency at higher dose | Severity | Mitigation |
|---|---|---|---|
| Nausea on dose escalation | Very common (~25–30%) | Mild to moderate, transient | Slower titration, smaller meals, ginger, anti-emetics if needed |
| Reflux / constipation | Common | Mild | Fibre 30 g+/day, water 2.5 L+/day |
| Lean mass loss acceleration | Common without resistance training | Long-term metabolic cost | Protein 1.6–2.2 g/kg + 2x weekly resistance training |
| Hypoglycaemia (with insulin/SU) | Common in T2D combo therapy | Can be serious | Reduce insulin/SU when escalating; monitor closely |
| Gallbladder events | Uncommon | Can be serious | Avoid very rapid additional calorie restriction |
| Pancreatitis (boxed class warning) | Rare | Serious | Persistent epigastric pain → stop and seek care |
| Fatigue / “low-energy week” | Common in calorie-cut phase | Mild, usually 7–10 days | Maintain electrolytes, sleep regularly |
The single most underrated risk during a plateau-break is accelerated lean mass loss. It is invisible on the scale — the kilo that comes off looks the same as fat. But every kilo of lost lean tissue lowers resting metabolic rate by roughly 13–25 kcal/day permanently, which makes the next plateau harder to break and the eventual maintenance phase harder to hold. Protein and resistance training are not optional add-ons; they are the floor on which dose-escalation works.
There is no labelled dose adjustment for plateau-breaking. The recommended path is the labelled titration schedule, taken to its next step when previous-dose tolerance is stable.
What does the research say about the GLP-1 plateau?
The published literature directly addresses the plateau shape, the dose-response slope, and the durability of effect once dose is held steady. The five studies below are the most-cited evidence on those points.
| Study | Year | Population | Plateau-relevant finding | Source |
|---|---|---|---|---|
| STEP-1 (Wilding et al.) | 2021 | 68-week RCT, obesity | Semaglutide 2.4 mg produces steep loss months 1–3, asymptote by ~month 16. The published mean curve is the canonical plateau shape. | NEJM |
| SURMOUNT-1 (Jastreboff et al.) | 2022 | 72-week RCT, obesity | Tirzepatide 15 mg produces the same shape, deeper. Plateau on 5 mg appears earlier than on 10 or 15 mg — direct evidence dose escalation extends the active losing phase. | NEJM |
| STEP-4 (Rubino et al.) | 2021 | Continuation vs withdrawal at week 20 | Continuing the drug at the same dose past the apparent slowdown still produces durable additional loss out to week 68. | JAMA |
| Rosenbaum et al. (metabolic adaptation) | 2008–2015 | Weight-reduced individuals | Resting metabolic rate falls 200–400 kcal/day beyond what body-mass loss alone predicts (adaptive thermogenesis). | Am J Physiol & Int J Obesity |
| Cava et al. (protein in calorie restriction) | 2017 | Review | Higher protein (1.2–1.6 g/kg) preserves lean mass during weight loss; very-high (1.8–2.2 g/kg) further protects lean tissue without increased risk. | Advances in Nutrition |
A few caveats. The trial mean curves describe averages — an individual experience can plateau much earlier or later. The dose-response evidence in SURMOUNT and STEP shows the labelled titration extends weight loss, but does not promise it for any given person. Early studies indicate that combining dose-escalation with protein-led lifestyle scaffolding outperforms either alone, but no head-to-head trial has tested the eight-lever stack we lay out below.
Plateau-breaking strategies — comparison
Most clinicians stack interventions rather than pick one. The table below shows each lever’s evidence base, expected magnitude, and the kind of plateau it addresses best.
| Strategy | Evidence quality | Expected magnitude | Best when… |
|---|---|---|---|
| Titrate dose up | RCT-grade (SURMOUNT, STEP) | Large (extends active loss months) | You are below labelled max and tolerating current dose |
| Protein floor + resistance training | RCT & meta-analysis | Moderate — mostly protects future TDEE | Any plateau (always indicated) |
| Recalculate calorie target | Indirect / first-principles | Moderate when intake has drifted up | Tracking suggests intake = current maintenance |
| Switch agent (sema → tirz) | RCT (SURPASS-2 head-to-head) | Large — deeper effect ceiling | Already on max semaglutide, plateaued, want more loss |
| Sleep optimisation | Observational + mechanistic | Small to moderate | Sleep is <7 hours/night or fragmented |
| Diet break / refeed | Limited (MATADOR trial) | Small, mostly psychological | Adherence fatigue is the real bottleneck |
| Confirm injection technique | Practical / pharmacokinetic | Variable — rules out drug-loss | Anyone — cheap to check |
| Accept the plateau | Clinical judgement | Zero further loss; protects health | BMI in healthy range; goal already met |
For deeper compare-and-contrast on agent switching, see our breakdowns of Ozempic vs Mounjaro and retatrutide vs tirzepatide vs semaglutide. For dose-fine-tuning, the Ozempic dosage chart shows the labelled titration map.
How to break a month-4 GLP-1 plateau — the 8-lever protocol
The order below is the order most obesity-medicine clinicians work through. Start at #1 and only move down the list if the higher-yield levers don’t fit your situation.
1. Confirm dose is at (or escalating toward) the labelled maximum
For semaglutide that’s 2.4 mg weekly; for tirzepatide 15 mg weekly. If you’re below those and tolerating your current dose, dose escalation is almost always the highest-yield single change. Discuss with your prescriber.
2. Verify injection technique
A subcutaneous injection should produce a small skin bleb, not bleeding or a tingle. Make sure you’re rotating sites weekly, hitting the abdomen / thigh / upper arm correctly, and not injecting into muscle. See our deep-dive on semaglutide injection sites.
3. Set a protein floor and hold it
Aim for 1.6–2.2 g/kg of body weight per day. For an 80 kg person that’s 130–175 g/day, every day. Track it for at least 7 days to confirm. Protein is the single highest-yield macronutrient change for both satiety and lean mass preservation.
4. Add or formalise resistance training
Two sessions per week minimum, full-body, working to near-failure. The point is not aesthetic — it is preserving the lean mass that drives your resting metabolic rate.
5. Track intake for 7 days (just once)
You may discover you’ve drifted to maintenance intake without noticing. Most plateaus include a “calorie creep” component. One honest week of tracking is diagnostic; you don’t need to live in a food log permanently.
6. Sleep audit
Seven hours minimum, regular bedtime, dark room, no alcohol within 3 hours of sleep. Sleep loss directly raises ghrelin and cortisol — both push appetite up.
7. Consider an agent switch
If you’ve maxed semaglutide and have stalled, switching to tirzepatide (or, when available, a triple agonist like retatrutide) often re-opens the losing phase. The SURPASS-2 head-to-head suggests tirzepatide produces ~4 percentage points more weight loss than semaglutide at maximum doses.
8. Consider whether the plateau is the answer
If BMI is now in the healthy range, the body composition you wanted is here, and the plateau has held for 4–8 weeks, that may simply be your new defended weight. The clinically correct move at that point is the transition to a maintenance protocol — not pushing the dose higher. The companion guide on what happens when you stop taking Ozempic covers the maintenance and rebound dynamics in detail.
Browse our weight-loss range at MedsBase for the agent options if a switch is on the table, or read the Ozempic buying guide if dose timing or supply is part of your plateau equation.
📋 The 8-lever plateau-break checklist
Cheap-and-fast: sleep audit, water 2.5 L, recheck injection technique. Medium effort: protein floor, 7-day intake track, recalculate calorie target. Bigger interventions: dose escalation to labelled max, agent switch, structured resistance training. Strategic check: is the plateau actually a maintenance signal?
Frequently Asked Questions
Why have I stopped losing weight on Ozempic at month 4?
Most month-4 plateaus are multi-causal: metabolic adaptation has lowered your resting calorie burn, your current dose is sub-maximal for your now-lower body weight, snacking and protein deficit have crept in, and lean mass loss may be reducing your daily expenditure further. None of this means Ozempic has stopped working. The published trial weight curves show the same shape — steep early, slowing around month 4, asymptote around month 16.
How long does the GLP-1 plateau last?
Most plateaus last 2–6 weeks if no intervention is made; some last 8–12 weeks. Plateaus that persist beyond 12 weeks typically signal that the body has reached an energy-balance equilibrium and one of the eight levers needs to change — dose, protein, training, sleep or agent. A plateau under 14 days is more likely “weight noise” than a true plateau.
Should I increase my Ozempic dose to break a plateau?
If you are below the labelled maximum (2.4 mg for semaglutide, 15 mg for tirzepatide), dose escalation is usually the highest-yield single change — discuss with your prescriber. RCT evidence (SURMOUNT-1, STEP-1) shows higher doses extend the active losing phase. If you are already at the maximum, dose escalation is no longer the lever; agent switch, protein, training and sleep become more useful.
Will my weight loss restart on its own?
Often, yes — but not always quickly. Some plateaus resolve in 2–3 weeks without any change; others harden into the body’s new maintenance level. The diagnostic question is whether your intake equals your current maintenance calorie need. If it does, the scale won’t move until intake drops, output rises, or the drug effect deepens (dose or agent).
Can I take a break from Ozempic to reset the plateau?
No — this almost always backfires. Taking a break causes weight regain (the published STEP-1 extension shows ~67% regained within a year of stopping), and restarting from a lower dose loses time and momentum. See our guide on stopping Ozempic and the rebound effect for the full discontinuation dynamics.
Does switching from Ozempic to Mounjaro help with a plateau?
For many people, yes. The SURPASS-2 head-to-head trial showed tirzepatide produces ~4 percentage points greater weight loss than semaglutide at maximum doses, mostly attributed to the added GIP receptor activity. People who plateau at the top of the semaglutide curve often re-open meaningful loss when switched to tirzepatide. See our Ozempic vs Mounjaro comparison for the trial detail.
How much protein do I need on Ozempic?
Aim for 1.6–2.2 g per kg of body weight per day. For an 80 kg person, that’s 130–175 g/day. The lower end (1.2–1.6 g/kg) protects against most lean mass loss; the upper end (1.8–2.2 g/kg) is closer to optimal for body-composition outcomes. Reduced appetite on GLP-1 therapy makes hitting this target genuinely hard — protein shakes, Greek yoghurt, eggs and lean meat at every eating occasion are the practical fix.
Is the month-4 plateau actually my body’s “set point”?
Sometimes — but rarely at month 4. The body does have a defended weight range that is hard to push below without sustained intervention, but most people on GLP-1 therapy can lose well beyond month 4 with appropriate dose and lifestyle scaffolding. The published trial curves show meaningful additional loss through month 12–16 in most participants. A true set-point plateau is more likely after 9–12 months of treatment, not after 4.
Should I exercise more aggressively during a plateau?
Yes for resistance training, modestly yes for cardio. Resistance training preserves the lean mass that drives your daily metabolic rate — do this regardless of plateau status. Cardio adds modest daily calorie burn but the bigger lever is preserving lean tissue. Two strength sessions a week, working close to failure, is the high-yield prescription. Adding three days of brisk walking on top is reasonable but not essential.
The bottom line
The month-4 GLP-1 plateau is a feature, not a bug. Every published Phase 3 trial weight curve shows the same shape: a steep initial drop through month 3, a gradual slowdown through month 12, and an asymptote by month 16. Hitting the slowdown around week 14–20 means your medication is working exactly as it did in the trials.
The plateau is also fixable in most cases. The single highest-yield lever is usually dose escalation toward the labelled maximum — the same titration that the SURMOUNT and STEP trials used. After that, the floor of protein at 1.6–2.2 g/kg, resistance training twice a week, and an honest 7-day intake check identify and correct the next layer of cause. Sleep, technique, and agent-switch options come in below those.
Sometimes the right answer is to stop pushing. If your BMI is in the healthy range and the plateau has held for 4–8 weeks, that may be your body’s new defended weight. The clinically correct move is the transition to maintenance — protein, training, sleep, and the dose level that keeps you there. Browse generic semaglutide or compare the broader range in our guide to weight-loss medications if a dose change or agent switch is your next step.
⚕️ Medical Disclaimer
This article is for educational purposes only and does not replace individual medical advice. Decisions about dose escalation, agent switching, or pausing GLP-1 therapy should be made with a qualified clinician who knows your full history — particularly if you have type 2 diabetes, take insulin or sulfonylureas, have a personal or family history of pancreatitis, medullary thyroid carcinoma, MEN-2 syndrome, or active gallbladder disease, or are pregnant or planning pregnancy. The class warnings on GLP-1 medications (pancreatitis, thyroid C-cell tumour signal, gallbladder events) apply at every dose and are not eliminated by stalling or escalation.
Further reading: STEP-1 (Wilding et al., NEJM 2021) · SURMOUNT-1 (Jastreboff et al., NEJM 2022) · STEP-4 (Rubino et al., JAMA 2021) · Cava et al. on protein in calorie restriction (Advances in Nutrition, 2017) · NHS: Managing your weight.
Written by
Sophie ChenPharmaceutical Content Researcher · 8 years experience
Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.